S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

BCRX BioCryst Pharmaceuticals Inc

7.70

-0.16 (-2.04%)

Mar 07 2025 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more BioCryst Pharmaceuticals Charts.

BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more BioCryst Pharmaceuticals Charts.

BioCryst Pharmaceuticals Inc News

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Thursday 6 March 2025 (3 days ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 4 March 2025 (4 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 4 March 2025 (5 days ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Tuesday 25 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 24 February 2025 (2 weeks ago) • Edgar (US Regulatory)

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
Monday 24 February 2025 (2 weeks ago) • GlobeNewswire Inc.

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
Monday 24 February 2025 (2 weeks ago) • GlobeNewswire Inc.

BioCryst to Present at Upcoming Investor Conferences
Wednesday 19 February 2025 (3 weeks ago) • GlobeNewswire Inc.

BioCryst Launches ORLADEYO® (berotralstat) in Portugal
Wednesday 12 February 2025 (4 weeks ago) • GlobeNewswire Inc.

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
Monday 10 February 2025 (4 weeks ago) • GlobeNewswire Inc.

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
Monday 10 February 2025 (4 weeks ago) • GlobeNewswire Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 4 February 2025 (1 month ago) • GlobeNewswire Inc.

More BioCryst Pharmaceuticals Inc News Articles

Intesa Sanpaolo

Intesa Sanpaolo

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions